Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treating prostate cancer with anti-ErbB2 antibodies

A prostate cancer and antibody technology, applied in antibody medical components, antibodies, anti-tumor drugs, etc., can solve problems such as unreported mutations

Inactive Publication Date: 2008-04-16
GENENTECH INC
View PDF59 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no point mutation similar to that in the neu proto-oncogene has been reported for human tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treating prostate cancer with anti-ErbB2 antibodies
  • Treating prostate cancer with anti-ErbB2 antibodies
  • Treating prostate cancer with anti-ErbB2 antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0260] Production and Characterization of Monoclonal Antibody 2C4

[0261] Murine monoclonal antibodies 2C4, 7F3 and 4D5 that specifically bind to the ErbB2 extracellular domain were produced as described by Fendly et al., Cancer Research 50: 1550-1558 (1990). Briefly, DNA produced as described by Hudziak et al., Proc. Natl. Acad. Sci. (USA) 84:7158-7163 (1987) was collected in phosphate buffered saline containing 25 mM EDTA. NIH 3T3 / HER2-3 400 cells (expressing approximately 1 x 10 ErbB2 molecules / cell) and used to immunize BALB / c mice. At 0, 2, 5, and 7 weeks, mice were injected intraperitoneally with 10 dissolved in 0.5 ml PBS. 7 cells. Mice bearing immunoprecipitated 32P-labeled ErbB2 antiserum were injected intraperitoneally with wheat germ agglutinin-agarose (WGA) purified ErbB2 membrane extracts at 9 and 13 weeks. This step was followed by iv injection of 0.1 ml of the ErbB2 preparation and fusion of splenocytes with the mouse myeloma line X63-Ag8.653. Hybridoma ...

Embodiment 2

[0272] Blocking of HRG-dependent binding of ErbB2 to ErbB3 by monoclonal antibody 2C4

[0273] The ability of ErbB3 to bind ErbB2 was tested using a co-immunoprecipitation assay. will be 1.0×10 6 MCF7 or SK-BR-3 cells were seeded in 50:50 DMEM / Ham's F12 medium containing 10% fetal bovine serum (FBS) and 10 mM HEPES (growth medium) at pH 7.2 in 6-well tissue culture plates and allowed to adhere overnight. Cells were starved for 2 hours in serum-free growth medium before starting experiments.

[0274] Cells were washed briefly with phosphate-buffered saline (PBS) and then diluted with 100 nM into 0.2% w / v bovine serum albumin (BSA), RPMI medium for the indicated antibodies, with 10 mM HEPES (binding buffer) at pH 7.2 or Incubate with binding buffer alone (control). After 1 hour at room temperature, HRG was added to half of the wells (+) to a final concentration of 5 nM. A similar volume of binding buffer was added to the other well (-). The incubation was continued for a...

Embodiment 3

[0280] Humanized 2C4 Antibody and Affinity Matured 2C4 Antibody Variants

[0281] The variable domains of the murine monoclonal antibody 2C4 were first cloned into a vector that yielded mouse / human chimeric Fab fragments. Total RNA was isolated from hybridoma cells using the Stratagene RNA extraction kit following the manufacturer's protocol. The variable domains were amplified by RT PCR as described above, gel-purified and inserted into pUC119-based plasmid derivatives containing human kappa constant domains and human C H 1 domain (Carter et al. PNAS (USA) 89:4285 (1992); and US Pat. No. 5,821,337). The resulting plasmid was transformed into E. coli strain 16C9 for expression of the Fab fragment. Growth of cultures, induction of protein expression, and purification of Fab fragments were as described above (Werther et al. J. Immunol. 157:4986-4995 (1996); Presta et al. Cancer Research 57: 4593-4599 (1997)). Comparison of the inhibition of purified chimeric 2C4 Fab fragme...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

Description

field of invention [0001] The present invention relates to methods of treating prostate cancer using anti-ErbB2 antibodies. Background of the invention [0002] ErbB family receptor tyrosine kinases are important mediators of cell growth, differentiation and survival. This family of receptors includes 4 different members, they include epidermal growth factor receptor (EGFR or ErbB1), HER2 (ErbB2 or p185 neu ), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). [0003] EGFR, encoded by the erbBI gene, is associated with human malignancies. In particular, increased expression of EGFR has been observed in breast, bladder, lung, head, neck, and gastric cancers, as well as glioblastoma. Increased expression of the EGFR receptor is often associated with increased production of the EGFR ligand, transforming growth factor alpha (TGF-α), by the same tumor cells that lead to receptor activation through an autocrine stimulatory pathway. Baselga and Mendelsohn, Pharmac. Ther. 64:127-154 (1994...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61P35/00A61K31/337A61K47/48C07K16/32
CPCA61K47/48407A61K39/39558C07K2317/565C07K16/32A61K2039/505C07K2317/55C07K2317/24C07K2316/96C07K2317/73C07K2317/76A61K47/6809A61P31/00A61P35/00A61P43/00A61K31/365A61K31/335A61K2300/00A61K39/395
Inventor M.X.斯利科维斯基
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com